ORITAVANCIN DIPHOSPHATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2014)
Entry Type: Unknown
Molecule Category: Salt
UNII: VL1P93MKZN
Parent Compound: ORITAVANCIN

Structure
InChI Key PWTROOMOPLCZHB-BHYQHFGMSA-N
Smile CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.O=P(O)(O)O.O=P(O)(O)O
InChI
InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C86H103Cl3N10O34P2
Molecular Weight 1989.11
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Peptidoglycan inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Abscess 3 D000038 ClinicalTrials
Cellulitis 3 D002481 ClinicalTrials
Inflammation 3 D007249 ClinicalTrials
Skin Diseases 1 D012871 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
18.73
Skin and subcutaneous tissue disorders
14.42
Injury, poisoning and procedural complications
13.61
Cardiac disorders
8.44
Respiratory, thoracic and mediastinal disorders
7.3
Musculoskeletal and connective tissue disorders
7.21
Immune system disorders
6.8
Nervous system disorders
5.22
Gastrointestinal disorders
5.12
Vascular disorders
4.4
Investigations
2.77

Cross References

Resources Reference
ChEBI 83305
ChEMBL CHEMBL3989766
FDA SRS VL1P93MKZN
PubChem 53297457
CONTENTS